摘要
目的探讨术前希罗达化疗对结直肠癌患者外周血循环CK20mRNA影响及临床意义。方法四川都江堰市人民医院2011年10月至2013年10月收治的结直肠癌患者75例,随机分为试验组38例和对照组37例,试验组术前服用希罗达治疗1周后进行手术治疗,对照组给予安慰剂口服1周。手术日抽取两组患者外周静脉血10mL,采用real-timePCR的方法检测两组患者外周血CK20mRNA拷贝数有无差别。结果试验组希罗达口服1周后外周血CK20mRNA检测阳性21例(55%),对照组CK20mRNA检测阳性35例(95%),试验组CK20mRNA阳性率显著低于对照组(P<0.05);试验组CK20mRNA阳性患者其CK20mRNA相对含量显著低于对照组(P<0.05)。结论结直肠癌患者术前口服希罗达可显著降低患者外周血CK20mRNA阳性率及拷贝数。
Objective To evaluate the clinical efficacy of preoperative chemotherapy of Xeloda in patients with colorectal cancer for CK20mRNA. Methods Seventy five patients with colorectal cancer from Oct 2010 to Oct 2013 were included in this study. Of the 75 cases, 38 were allocated in the treatment group with Xeloda and other 37 patients with obvious. After 2 weeks of treatment, the CK20mRNA level of peripheral blood of the two groups were tested and compared between the two groups. Results In the experiments group, 21 patients had CK20mRNA positive and in the control group had 35 patients positive which dem- onstrated that the positive rate in control group was much higher than that of the treatment group （ P 〈0. 05）. And the relative copy number of CK20mRNA in the treatment was much higher than that of control group （ P 〈0. 05 ）. Conclusion Preoperative chemotherapy of Xeloda in patients with colorectal cancer could significantly decrease the relative copy number of CK20mRNA which may decrease the risk of recur- rence or metastasis.
出处
《结直肠肛门外科》
2014年第1期23-25,共3页
Journal of Colorectal & Anal Surgery
基金
成都市卫生局科学研究基金(编号:2011136)
